Prescient Therapeutics is aggressively pursuing the clinical and commercial development of two novel cancer compounds, PTX-200 and PTX-100.  The Company is conducting a number of clinical trials in the US, and has four open INDs allowed by the US FDA.  PTX-200 is currently progressing through Phase 1b/2a trials in breast and ovarian cancers and soon to begin an accruing patient for leukemia trials. These trials are being conducted at some of the most prestigious cancer centres in the United States.